PMID- 29387228
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 1
DP  - 2018 Jan
TI  - Oncogenic activity of insulin in the development of non-small cell lung 
      carcinoma.
PG  - 447-452
LID - 10.3892/ol.2017.7347 [doi]
AB  - Insulin is associated with the progression of numerous different types of cancer. 
      However, the association between insulin and non-small cell lung carcinoma 
      (NSCLC) remains unknown. The aim of the present study was to evaluate the role of 
      insulin in the proliferation, migration and drug resistance of NSCLC cells, and 
      to determine whether the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) 
      pathway was involved. NSCLC cells were treated with insulin in the absence or 
      presence of LY294002, an inhibitor of the PI3K/Akt pathway. Following 
      co-incubation with insulin, cell proliferation and drug resistance were measured 
      by MTT; cell migration was examined by wound healing and Transwell assays; and 
      the expression of cyclin A, proliferating cell nuclear antigen (PCNA), p27, 
      matrix metalloproteinase 3 (MMP3), P-gp and proteins involved in the PI3K/Akt 
      pathway were assessed via western blotting. The results of the current study 
      demonstrated that insulin enhanced the proliferation, migration and drug 
      resistance of NSCLC cells. Correspondingly, insulin upregulated the expression of 
      cyclin A, PCNA, MMP3, P-gp and downregulated p27 expression in NSCLC cells. 
      Following treatment with insulin, it was demonstrated that phospho-Akt expression 
      increased in a dose-dependent manner. However, the effects of insulin on NSCLC 
      cells was inhibited by the PI3K/Akt pathway inhibitor LY294002. Therefore, the 
      results of the current study indicate that insulin is associated with the 
      development of NSCLC by activating the PI3K/Akt pathway. This may improve 
      understanding of the mechanism of action of insulin in NSCLC in the future.
FAU - Jiang, Jie
AU  - Jiang J
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen 
      University, Xiamen, Fujian 361003, P.R. China.
FAU - Ren, Hong-Yue
AU  - Ren HY
AD  - Department of Pathology, The Affiliated Southeast Hospital of Xiamen University, 
      Zhangzhou, Fujian 363000, P.R. China.
FAU - Geng, Guo-Jun
AU  - Geng GJ
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen 
      University, Xiamen, Fujian 361003, P.R. China.
FAU - Mi, Yan-Jun
AU  - Mi YJ
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen 
      University, Xiamen, Fujian 361003, P.R. China.
FAU - Liu, Yu
AU  - Liu Y
AD  - Department of Biobank, The First Affiliated Hospital of Xiamen University, 
      Xiamen, Fujian 361003, P.R. China.
FAU - Li, Ning
AU  - Li N
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen 
      University, Xiamen, Fujian 361003, P.R. China.
FAU - Yang, Shu-Yu
AU  - Yang SY
AD  - Department of Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen 
      University, Xiamen, Fujian 361003, P.R. China.
FAU - Shen, Dong-Yan
AU  - Shen DY
AD  - Department of Biobank, The First Affiliated Hospital of Xiamen University, 
      Xiamen, Fujian 361003, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20171103
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5768075
OTO - NOTNLM
OT  - insulin
OT  - non-small cell lung carcinoma
OT  - oncogenic activity
OT  - phosphoimositide 3-kinase/protein kinase B
EDAT- 2018/02/02 06:00
MHDA- 2018/02/02 06:01
PMCR- 2017/11/03
CRDT- 2018/02/02 06:00
PHST- 2016/07/14 00:00 [received]
PHST- 2017/08/17 00:00 [accepted]
PHST- 2018/02/02 06:00 [entrez]
PHST- 2018/02/02 06:00 [pubmed]
PHST- 2018/02/02 06:01 [medline]
PHST- 2017/11/03 00:00 [pmc-release]
AID - OL-0-0-7347 [pii]
AID - 10.3892/ol.2017.7347 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Jan;15(1):447-452. doi: 10.3892/ol.2017.7347. Epub 2017 Nov 3.